Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits

Introduction: Neurodegenerative diseases are incurable debilitating disorders of the nervous system that affect approximately 30 million people worldwide. Despite profuse efforts attempting to define the molecular mechanisms underlying neurodegeneration, many aspects of these pathologies remain elusive. The novelty of their mechanisms represents a challenge to biology, to their related biomarkers identification and drug discovery. Because of their multifactorial aspects and complexity, gene expression analysis platforms have been extensively used to investigate altered pathways during degeneration and to identify potential biomarkers and drug targets. Areas covered: This work offers an overview of the gene expression profiling studies carried out on Alzheimer's disease, Huntington's disease, Parkinson's disease and prion disease specimens. Therapeutic approaches are also discussed. Expert opinion: Although many therapeutic approaches have been tested, some of them acting on several altered cellular pathways, no effective cures for these neurodegenerative diseases have been identified. Microarray technology must be associated with functional proteomics and physiology in an effort to identify specific and selective biomarkers and druggable targets, thus allowing the successful discovery of disease-modifying therapeutic treatments.

[1]  J. Wilkinson,et al.  The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge? , 2012, Journal of clinical pharmacology.

[2]  D. Galimberti,et al.  Progress in Alzheimer’s disease , 2012, Journal of Neurology.

[3]  Zhong Wang,et al.  Next-generation transcriptome assembly , 2011, Nature Reviews Genetics.

[4]  L. Defebvre,et al.  Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation , 2011, Neurobiology of Aging.

[5]  Pei Wang,et al.  Gene expression profiling of peripheral blood leukocytes identifies and validates ABCB1 as a novel biomarker for Alzheimer's disease , 2011, Neurobiology of Disease.

[6]  Y. Ohyagi Apomorphine treatment in Alzheimer's mice promoting amyloid-beta degradation , 2011, Alzheimer's & Dementia.

[7]  David Gomez-Cabrero,et al.  ParkDB: a Parkinson’s disease gene expression database , 2011, Database J. Biol. Databases Curation.

[8]  Daiga Heisters,et al.  Parkinson's: symptoms, treatments and research. , 2011, British journal of nursing.

[9]  A. Young,et al.  Milestones in Huntington disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[10]  J. Kril,et al.  Understanding the pathogenesis of Alzheimer’s disease: will RNA‐Seq realize the promise of transcriptomics? , 2011, Journal of neurochemistry.

[11]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[12]  H. Federoff,et al.  Therapeutic potential of vaccines for Alzheimer's disease. , 2011, Immunotherapy.

[13]  F. Jirik,et al.  Prion protein expression level alters regional copper, iron and zinc content in the mouse brain. , 2011, Metallomics : integrated biometal science.

[14]  T. Tabira,et al.  Apomorphine treatment in Alzheimer mice promoting amyloid‐β degradation , 2011, Annals of neurology.

[15]  M. Menéndez-González,et al.  Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. , 2011, Current pharmaceutical design.

[16]  M. Wilkins,et al.  Whole Transcriptome Sequencing Reveals Gene Expression and Splicing Differences in Brain Regions Affected by Alzheimer's Disease , 2011, PloS one.

[17]  L. Bubacco,et al.  Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? , 2011, Molecular Neurodegeneration.

[18]  Sandro Sorbi,et al.  Meta-analysis of the association between variants in SORL1 and Alzheimer disease. , 2011, Archives of neurology.

[19]  Huaxi Xu,et al.  APP processing in Alzheimer's disease , 2011, Molecular Brain.

[20]  Xiongwei Zhu,et al.  Frontiers in Alzheimer’s disease therapeutics , 2011, Therapeutic advances in chronic disease.

[21]  T. Amit,et al.  Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. , 2010, Progress in neurobiology.

[22]  Manuel B. Graeber,et al.  PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease , 2010, Science Translational Medicine.

[23]  M. Zampieri,et al.  Gene expression profiling to identify druggable targets in prion diseases , 2010, Expert opinion on drug discovery.

[24]  Anil Kumar,et al.  Huntington’s disease: pathogenesis to animal models , 2010, Pharmacological reports : PR.

[25]  C. Tanner,et al.  Urate as a predictor of the rate of clinical decline in Parkinson disease. , 2009, Archives of neurology.

[26]  G. Legname,et al.  De novo mammalian prion synthesis , 2009, Prion.

[27]  Lisa M. Miller,et al.  Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease , 2009, NeuroImage.

[28]  Isidro Ferrer,et al.  Unexpected expression of α- and β-globin in mesencephalic dopaminergic neurons and glial cells , 2009, Proceedings of the National Academy of Sciences.

[29]  J. Olcese,et al.  Protection against cognitive deficits and markers of neurodegeneration by long‐term oral administration of melatonin in a transgenic model of Alzheimer disease , 2009, Journal of pineal research.

[30]  M. Sano,et al.  An update on treatment and prevention strategies for Alzheimer’s disease , 2009, Current neurology and neuroscience reports.

[31]  V. Daggett,et al.  The consequences of pathogenic mutations to the human prion protein. , 2009, Protein engineering, design & selection : PEDS.

[32]  Mark A. Smith,et al.  Nanoparticle–chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease , 2009, Neuroscience Letters.

[33]  M. Graeber Biomarkers for Parkinson's disease , 2009, Experimental Neurology.

[34]  Yongliang Yang,et al.  Target discovery from data mining approaches. , 2009, Drug discovery today.

[35]  B. Mollenhauer,et al.  Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration , 2008, Experimental Neurology.

[36]  I. Schlesinger,et al.  Uric acid in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[37]  A. Kurz,et al.  Parkinson patient fibroblasts show increased alpha-synuclein expression , 2008, Experimental Neurology.

[38]  Mary Sano,et al.  Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.

[39]  A. Lang,et al.  Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.

[40]  Eric M Reiman,et al.  Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. , 2008, Physiological genomics.

[41]  L. Rydzewska,et al.  Systematic review of therapeutic interventions in human prion disease , 2008, Neurology.

[42]  H. Diana Rosas,et al.  Neuroprotection for Huntington’s disease: Ready, set, slow , 2008, Neurotherapeutics.

[43]  R. Montironi,et al.  Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer. , 2008, International journal of clinical and experimental pathology.

[44]  R. Faull,et al.  Assessing RNA quality in postmortem human brain tissue. , 2008, Experimental and molecular pathology.

[45]  Adriano Aguzzi,et al.  Molecular mechanisms of prion pathogenesis. , 2008, Annual review of pathology.

[46]  S. Leurgans,et al.  Neuronal LR11/sorLA expression is reduced in mild cognitive impairment , 2007, Annals of neurology.

[47]  George Perry,et al.  Evidence for the role of luteinizing hormone in Alzheimer disease. , 2007, Endocrine, metabolic & immune disorders drug targets.

[48]  John Collinge,et al.  A General Model of Prion Strains and Their Pathogenicity , 2007, Science.

[49]  J. Cha,et al.  Transcriptional signatures in Huntington's disease , 2007, Progress in Neurobiology.

[50]  Bjørn K. Alsberg,et al.  A framework for significance analysis of gene expression data using dimension reduction methods , 2007, BMC Bioinformatics.

[51]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[52]  Paul Greengard,et al.  Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies , 2007, Proceedings of the National Academy of Sciences.

[53]  M. Rezak Current pharmacotherapeutic treatment options in Parkinson's disease. , 2007, Disease-a-month : DM.

[54]  Alun Williams,et al.  Simvastatin treatment prolongs the survival of scrapie-infected mice , 2007, Neuroreport.

[55]  K. Lunetta,et al.  The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease , 2007, Nature Genetics.

[56]  J. Growdon,et al.  Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.

[57]  F. Cohen,et al.  Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes , 2006, Proceedings of the National Academy of Sciences.

[58]  D. Lütjohann,et al.  Simvastatin prolongs survival times in prion infections of the central nervous system. , 2006, Biochemical and biophysical research communications.

[59]  J. Kleinman,et al.  Critical Factors in Gene Expression in Postmortem Human Brain: Focus on Studies in Schizophrenia , 2006, Biological Psychiatry.

[60]  T. Montine,et al.  LR11/SorLA Expression Is Reduced in Sporadic Alzheimer Disease but not in Familial Alzheimer Disease , 2006, Journal of neuropathology and experimental neurology.

[61]  J. Collinge,et al.  A systematic review of prion therapeutics in experimental models. , 2006, Brain : a journal of neurology.

[62]  A. Bush,et al.  The Role of Metal Ions in Neurology. An Introduction , 2006 .

[63]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[64]  L. Moran,et al.  Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson’s disease , 2006, Neurogenetics.

[65]  Charles M Perou,et al.  Evaluating the comparability of gene expression in blood and brain , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[66]  J. Olson,et al.  Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.

[67]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[68]  L. Moran,et al.  Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson’s disease , 2006, Neurogenetics.

[69]  Ian J. Reynolds,et al.  Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures , 2005, Neurobiology of Disease.

[70]  Jingwen Liu,et al.  Synuclein Gamma Inhibits the Mitotic Checkpoint Function and Promotes Chromosomal Instability of Breast Cancer Cells , 2005, Breast Cancer Research and Treatment.

[71]  J. Lucas,et al.  Full Motor Recovery Despite Striatal Neuron Loss and Formation of Irreversible Amyloid-Like Inclusions in a Conditional Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.

[72]  A. Matus MARCKS for Maintenance in Dendritic Spines , 2005, Neuron.

[73]  S. Mandel,et al.  Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin‐Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC‐70 , 2005, Annals of the New York Academy of Sciences.

[74]  H. Kretzschmar,et al.  Cerebral gene expression profiles in sporadic Creutzfeldt–Jakob disease , 2005, Annals of neurology.

[75]  A. Hannan Novel therapeutic targets for Huntington’s disease , 2005, Expert opinion on therapeutic targets.

[76]  R. Brookmeyer,et al.  Reduced risk of Alzheimer’s disease with high folate intake: The Baltimore Longitudinal Study of Aging , 2005, Alzheimer's & Dementia.

[77]  Ling Lin,et al.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. , 2005, Human molecular genetics.

[78]  R. Jensen,et al.  Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. , 2005, Archives of neurology.

[79]  W. Noble,et al.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[80]  G. Pasinetti,et al.  From proteomics to biomarker discovery in Alzheimer's disease , 2005, Brain Research Reviews.

[81]  N. Hattori,et al.  Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease , 2005, Neurology.

[82]  J. Collins,et al.  Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks , 2005, Nature Biotechnology.

[83]  N. Greig,et al.  Inhibition of P53-related apoptosis had no effect on PrPSc accumulation and prion disease incubation time , 2005, Neurobiology of Disease.

[84]  R. Dingledine,et al.  Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism , 2005, Neurobiology of Disease.

[85]  J. Grimm,et al.  Molecular basis for catecholaminergic neuron diversity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[86]  A. Levey,et al.  Loss of apolipoprotein E receptor LR11 in Alzheimer disease. , 2004, Archives of neurology.

[87]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[88]  M. Beal,et al.  Experimental therapeutics in transgenic mouse models of Huntington's disease , 2004, Nature Reviews Neuroscience.

[89]  Joachim Klose,et al.  Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice* , 2004, Journal of Biological Chemistry.

[90]  B. Winblad,et al.  Aspirin, NSAIDs, Risk of Dementia, and Influence of the Apolipoprotein E Epsilon 4 Allele in an Elderly Population , 2004, Neuroepidemiology.

[91]  M. Salmona,et al.  Squalestatin Cures Prion-infected Neurons and Protects Against Prion Neurotoxicity* , 2004, Journal of Biological Chemistry.

[92]  C. Lines,et al.  Rofecoxib , 2004, Neurology.

[93]  R. Yasuda,et al.  Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. , 2003, Brain : a journal of neurology.

[94]  E. Sigurdsson,et al.  Copper Chelation Delays the Onset of Prion Disease* , 2003, Journal of Biological Chemistry.

[95]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[96]  Patrik Brundin,et al.  Huntington's disease: a synaptopathy? , 2003, Trends in molecular medicine.

[97]  J. Collins,et al.  Inferring Genetic Networks and Identifying Compound Mode of Action via Expression Profiling , 2003, Science.

[98]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[99]  Michael P H Stumpf,et al.  Balancing Selection at the Prion Protein Gene Consistent with Prehistoric Kurulike Epidemics , 2003, Science.

[100]  P. Julien,et al.  Lipoprotein Lipase Affects the Survival and Differentiation of Neural Cells Exposed to Very Low Density Lipoprotein* , 2003, The Journal of Biological Chemistry.

[101]  P. Coleman,et al.  Defects in expression of genes related to synaptic vesicle traffickingin frontal cortex of Alzheimer’s disease , 2003, Neurobiology of Disease.

[102]  H. Lehrach,et al.  Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[103]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[104]  M. Ball,et al.  Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: Transcription and neurotrophic factor down‐regulation and up‐regulation of apoptotic and pro‐inflammatory signaling , 2002, Journal of neuroscience research.

[105]  R. Hébert,et al.  Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. , 2002, American journal of epidemiology.

[106]  J. Drisko The Use of Antioxidants in Transmissible Spongiform Encephalopathies: A Case Report , 2002, Journal of the American College of Nutrition.

[107]  Danh V. Nguyen,et al.  Tumor classification by partial least squares using microarray gene expression data , 2002, Bioinform..

[108]  J M Lee,et al.  A gene expression profile of Alzheimer's disease. , 2001, DNA and cell biology.

[109]  M. Murphy,et al.  Development of lipophilic cations as therapies for disorders due to mitochondrial dysfunction , 2001, Expert opinion on biological therapy.

[110]  T. Sherer,et al.  Complex I and Parkinson's Disease , 2001, IUBMB life.

[111]  P. O'Brien,et al.  Elevated gonadotropin levels in patients with Alzheimer disease. , 2001, Mayo Clinic proceedings.

[112]  P. Scheltens,et al.  Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study , 2001, The Lancet.

[113]  A. Czernik,et al.  Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique , 2001, Neuroscience Letters.

[114]  J. Parks,et al.  Neurotoxic Aβ peptides increase oxidative stress in vivo through NMDA‐receptor and nitric‐oxide‐synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro , 2001, Journal of neurochemistry.

[115]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[116]  H J Koch,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[117]  Ash A. Alizadeh,et al.  'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns , 2000, Genome Biology.

[118]  Atkinson,et al.  An Association of Elevated Serum Gonadotropin Concentrations and Alzheimer Disease? , 2000, Journal of neuroendocrinology.

[119]  René Hen,et al.  Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.

[120]  S. Kuroda,et al.  Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson’s disease: relationship to clinical data , 1999, Journal of the Neurological Sciences.

[121]  Stanley B. Prusiner,et al.  Nobel Lecture: Prions , 1998 .

[122]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[123]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[124]  H. Ushijima,et al.  Effect of Flupirtine on Bcl-2 and Glutathione Level in Neuronal Cells Treatedin Vitrowith the Prion Protein Fragment (PrP106-126) , 1997, Experimental Neurology.

[125]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[126]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[127]  S. Prusiner,et al.  Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform [published erratum appears in J Cell Biol 1995 Jul;130(2):501] , 1995, The Journal of cell biology.

[128]  G. Macchi,et al.  Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy. , 1992, Journal of Infectious Diseases.

[129]  Christopher A. Ross,et al.  Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease , 1991, Neuroscience Letters.

[130]  P. Casaccia,et al.  Amphotericin B: a novel class of antiscrapie drugs. , 1989, The Journal of infectious diseases.

[131]  W. Gibb,et al.  THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE , 1989, Neuropathology and applied neurobiology.

[132]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[133]  D. Schlessinger,et al.  Interaction of plasma proteins and lipoproteins with amphotericin B. , 1984, The Journal of infectious diseases.

[134]  L. Schiffer,et al.  Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.

[135]  Katunina Ea,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[136]  R. Uitti,et al.  Autosomal dominant Parkinson's disease. , 2012, Parkinsonism & related disorders.

[137]  Solve Sæbø,et al.  A gene expression pattern in blood for the early detection of Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[138]  S. Krobitsch,et al.  Huntington's disease: From molecular basis to therapeutic advances. , 2011, The international journal of biochemistry & cell biology.

[139]  M. Gerstein,et al.  RNA-Seq: a revolutionary tool for transcriptomics , 2009, Nature Reviews Genetics.

[140]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[141]  S. Dunnett,et al.  Pharmaceutical, cellular and genetic therapies for Huntington's disease. , 2006, Clinical science.

[142]  Deborah Gustafson,et al.  Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. , 2004, Archives of neurology.

[143]  A. Schapira,et al.  Genetic and environmental factors in the cause of Parkinson's disease , 2003, Annals of neurology.

[144]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[145]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[146]  G. Halliday,et al.  Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans , 1996, The Journal of comparative neurology.

[147]  A. Lbert,et al.  Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease , 2022 .